MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Lignende værker

• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  af: Pao, William, et al.
  Udgivet: (2005)
• Morphologic Features of Adenocarcinoma of the Lung Predictive of Response to the Epidermal Growth Factor Receptor Kinase Inhibitors Erlotinib and Gefitinib
  af: Zakowski, Maureen F., et al.
  Udgivet: (2009)
• Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
  af: Oxnard, Geoffrey R., et al.
  Udgivet: (2011)
• Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer
  af: Kuang, Yanan, et al.
  Udgivet: (2009)
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
  af: Pao, William, et al.
  Udgivet: (2005)